Venture Capital Deals and Investments
  • All Technology
  • AI
  • Autonomy
  • B2B Growth
  • Big Data
  • BioTech
  • ClimateTech
  • Consumer Tech
  • Crypto
  • Cybersecurity
  • DevOps
  • Digital Marketing
  • Ecommerce
  • EdTech
  • Enterprise
  • FinTech
  • GovTech
  • Hardware
  • HealthTech
  • HRTech
  • LegalTech
  • Nanotech
  • PropTech
  • Quantum
  • Robotics
  • SaaS
  • SpaceTech
AllNewsDealsSocialBlogsVideosPodcastsDigests

Venture Capital Pulse

EMAIL DIGESTS

Daily

Every morning

Weekly

Sunday recap

NewsDealsSocialBlogsVideosPodcasts
ENA Respiratory Raises $22.4M in Series B to Advance Antiviral Host Defense Programs
Series BVenture Capital

ENA Respiratory Raises $22.4M in Series B to Advance Antiviral Host Defense Programs

•October 22, 2025
•Oct 22, 2025
0

Participants

ENA Respiratory

ENA Respiratory

company

Bill & Melinda Gates Foundation

Bill & Melinda Gates Foundation

investor

Brandon Capital Partners

Brandon Capital Partners

investor

Stoic VC

Stoic VC

investor

Flu Lab

Flu Lab

investor

Uniseed

Uniseed

investor

Deal Summary

ENA Respiratory, a Melbourne clinical-stage pharmaceutical company developing antiviral host defense enhancers, secured $22.4M (AUD34M) in a Series B round led by existing and new backers to advance its clinical programs. Investors include the Gates Foundation, Flu Lab, Brandon Capital, Uniseed and Stoic Venture Capital.

0

Comments

Want to join the conversation?

Loading comments...